+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Autoimmune Disease Therapeutics Market by Therapeutic Types, Disease Type, Route of Administration, Therapeutic Application, End-User - Global Forecast 2026-2032- Product Image
Autoimmune Disease Therapeutics Market by Therapeutic Types, Disease Type, Route of Administration, Therapeutic Application, End-User - Global Forecast 2026-2032- Product Image
Sale

Autoimmune Disease Therapeutics Market by Therapeutic Types, Disease Type, Route of Administration, Therapeutic Application, End-User - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4995356
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Autoimmune Disease Therapeutics Market is projected to reach USD 209.53 Billion in 2026. It is expected to continue growing at a CAGR of 10.52%, reaching USD 382.33 Billion by 2032.

Autoimmune disease therapeutics address a broad set of chronic, immune-mediated conditions, including rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes, and autoimmune thyroid disorders. The National Institutes of Health recognizes more than 80 autoimmune diseases, many of which require long-term disease control rather than episodic treatment.

The market is being shaped by the expansion of biologics, biosimilars, targeted synthetic disease-modifying therapies, and precision immunology approaches. Demand is supported by earlier diagnosis, improved specialist referral pathways, and a growing emphasis on treat-to-target care models that measure remission, relapse prevention, organ protection, steroid-sparing benefits, and patient-reported outcomes.

Transformative Shifts in the Autoimmune Therapeutics Landscape

The autoimmune therapeutics landscape is shifting from broad immunosuppression toward pathway-specific immune modulation. Monoclonal antibodies, fusion proteins, Janus kinase inhibitors, TYK2 inhibition, B-cell depletion, interleukin blockade, integrin targeting, sphingosine-1-phosphate receptor modulation, and complement-directed strategies are enabling more individualized treatment decisions across inflammatory, dermatologic, neurologic, gastrointestinal, and rheumatologic indications.

At the same time, biosimilar adoption is changing payer negotiations and treatment access. Regulatory agencies, including the FDA and EMA, continue to support biosimilar pathways, while safety communications around some immunomodulators, including JAK inhibitors, have increased the importance of risk stratification, post-marketing surveillance, infection screening, vaccination planning, and shared decision-making between clinicians and patients.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative enabler across autoimmune drug discovery, clinical development, and commercialization. AI-supported target identification, multi-omics analysis, imaging interpretation, digital biomarkers, natural language processing, and real-world evidence analytics are helping researchers understand disease heterogeneity and identify patient subgroups more likely to respond to specific mechanisms of action.

In clinical operations, AI can improve protocol design, site selection, eligibility screening, adverse event detection, and patient retention when deployed with appropriate governance. For industry leaders, the strongest near-term value is expected where AI augments regulated workflows, supports pharmacovigilance, improves literature monitoring, and accelerates evidence generation without replacing clinical judgment or validated regulatory standards.

Key Regional Insights

North America remains a leading region for autoimmune disease therapeutics due to high specialist density, mature reimbursement systems, large clinical trial networks, and rapid uptake of innovative biologics and targeted therapies. The United States anchors regional activity through FDA approvals, payer-driven formulary management, specialty pharmacy infrastructure, and extensive real-world evidence generation, while Canada contributes through public-private care pathways, health technology assessment, and provincial reimbursement decision-making.

Europe benefits from centralized EMA regulatory processes, strong national reimbursement systems, established treatment guidelines, and broad biosimilar utilization, particularly across European Union markets. Asia-Pacific is gaining strategic importance as China, Japan, India, South Korea, Australia, and ASEAN health systems expand clinical development, biologics manufacturing, specialty care access, and patient assistance programs. Latin America shows rising demand through Brazil and Mexico as biosimilar availability, public procurement, and private insurance coverage shape access. The Middle East is advancing through hospital modernization and specialty medicine procurement in GCC health systems, while Africa remains highly heterogeneous, with autoimmune therapy adoption influenced by affordability, diagnostic capacity, specialist availability, cold-chain infrastructure, and reimbursement maturity.

Key Group Insights

The European Union is a major policy and access environment for autoimmune disease therapeutics, with centralized regulatory review, national pricing negotiations, health technology assessment processes, and strong biosimilar experience shaping competitive dynamics. G7 countries collectively influence clinical standards, payer evidence requirements, pharmacovigilance expectations, launch sequencing, and adoption of advanced immunology products through mature regulatory systems and specialist care networks.

BRICS markets are increasingly important for local manufacturing, clinical trial diversification, and broader treatment access, particularly as China, India, and Brazil expand biopharmaceutical capabilities and Russia prioritizes domestic registration and supply resilience. ASEAN markets offer long-term growth as health systems invest in specialty care, biologics access, and referral infrastructure, while GCC countries are prioritizing advanced hospital capacity, digital health systems, and access to innovative medicines. NATO membership is not a healthcare market grouping, but many NATO countries overlap with high-income European and North American systems that maintain advanced regulatory, procurement, pharmacovigilance, and clinical research capacity.

Key Country Insights

The United States leads autoimmune therapeutics innovation through extensive biomedical R&D activity, strong FDA regulatory infrastructure, broad clinical trial participation, and rapid specialty drug launches, while Canada emphasizes evidence-based reimbursement, health technology assessment, and equitable access across provincial systems. Mexico and Brazil are important Latin American markets where public procurement, private insurance, domestic regulatory pathways, and biosimilar availability affect therapy adoption.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are central to clinical research, guideline-led care, health technology assessment, and biosimilar-driven cost management, while Russia remains influenced by local registration, procurement policy, and manufacturing priorities. China is expanding biologics development, domestic innovation, and autoimmune clinical trial activity; India is strengthening biosimilar and cost-effective manufacturing capacity; Japan maintains high regulatory standards, specialist care access, and aging-population-driven demand for chronic disease management; South Korea is globally competitive in biosimilars and biologics manufacturing; and Australia supports advanced autoimmune care through structured reimbursement, specialist networks, and clinical guidelines.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated mechanisms of action, biomarker-supported patient selection, and evidence packages that demonstrate durable remission, relapse reduction, organ protection, steroid-sparing benefits, safety, and quality-of-life improvements. Commercial strategies should prepare for biosimilar competition, payer step therapy, indication-specific value assessments, and evolving treatment sequencing across rheumatology, dermatology, gastroenterology, neurology, endocrinology, and nephrology.

Organizations should also invest in real-world evidence, pharmacovigilance automation, patient support programs, adherence tools, and equitable access models. Partnerships with academic centers, specialty networks, diagnostics developers, contract research organizations, and AI-enabled analytics providers can improve trial precision, accelerate market access dossiers, and support lifecycle expansion across related autoimmune indications.

Research Methodology

This executive summary is based on secondary research from publicly available and authoritative sources, including regulatory agency materials, clinical trial registries, peer-reviewed literature, health technology assessment frameworks, treatment guidelines, pharmacovigilance updates, and recognized public health references such as NIH, FDA, EMA, WHO, and OECD resources where applicable.

The methodology emphasizes triangulation across clinical, regulatory, commercial, and regional indicators. Insights were validated by comparing disease burden evidence, treatment guidelines, product class developments, biosimilar policy trends, safety communications, reimbursement dynamics, and regional access conditions to identify consistent patterns shaping the autoimmune disease therapeutics market.

Conclusion

Autoimmune disease therapeutics are entering a more precise, evidence-intensive phase defined by biologic innovation, targeted oral therapies, biosimilar competition, improved safety monitoring, and AI-enabled development models. The strongest opportunities will emerge for organizations that can combine clinical differentiation with safety transparency, payer-relevant outcomes, and scalable access strategies.

As regional markets mature at different speeds, success will depend on aligning scientific innovation with local reimbursement realities, specialist capacity, regulatory expectations, and patient needs. Organizations that integrate precision medicine, real-world evidence, responsible AI, and equitable access planning into development and commercialization will be best positioned to lead the next phase of autoimmune care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Autoimmune Disease Therapeutics Market, by Therapeutic Types
7.1. Antihyperglycemics
7.2. Biologics
7.2.1. Fusion Proteins
7.2.2. Gene Therapy
7.2.3. Monoclonal Antibodies
7.3. Cytokine Inhibitors
7.4. Immunomodulators
7.5. Immunosuppressants
7.6. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
7.7. Phosphodiesterase Inhibitors
7.8. Small Molecules
7.8.1. Corticosteroids
7.8.2. JAK Inhibitors
8. Autoimmune Disease Therapeutics Market, by Disease Type
8.1. Inflammatory Bowel Disease
8.2. Lupus Erythematosus
8.3. Multiple Sclerosis
8.4. Psoriasis
8.5. Rheumatoid Arthritis
8.6. Type 1 Diabetes
9. Autoimmune Disease Therapeutics Market, by Route of Administration
9.1. Injectable
9.1.1. Intramuscular
9.1.2. Intravenous
9.1.3. Subcutaneous
9.2. Oral
10. Autoimmune Disease Therapeutics Market, by Therapeutic Application
10.1. Disease Progression Alteration
10.2. Immune System Modulation
10.3. Pain Management
10.4. Reduction of Inflammation
11. Autoimmune Disease Therapeutics Market, by End-User
11.1. Ambulatory Surgical Centers
11.2. Hospitals
11.3. Research Institutes
12. Asia-Pacific Autoimmune Disease Therapeutics Market
13. North America Autoimmune Disease Therapeutics Market
14. Latin America Autoimmune Disease Therapeutics Market
15. Europe Autoimmune Disease Therapeutics Market
16. Middle East Autoimmune Disease Therapeutics Market
17. Africa Autoimmune Disease Therapeutics Market
18. ASEAN Autoimmune Disease Therapeutics Market
19. GCC Autoimmune Disease Therapeutics Market
20. European Union Autoimmune Disease Therapeutics Market
21. BRICS Autoimmune Disease Therapeutics Market
22. G7 Autoimmune Disease Therapeutics Market
23. NATO Autoimmune Disease Therapeutics Market
24. United States Autoimmune Disease Therapeutics Market
25. Canada Autoimmune Disease Therapeutics Market
26. Mexico Autoimmune Disease Therapeutics Market
27. Brazil Autoimmune Disease Therapeutics Market
28. United Kingdom Autoimmune Disease Therapeutics Market
29. Germany Autoimmune Disease Therapeutics Market
30. France Autoimmune Disease Therapeutics Market
31. Russia Autoimmune Disease Therapeutics Market
32. Italy Autoimmune Disease Therapeutics Market
33. Spain Autoimmune Disease Therapeutics Market
34. China Autoimmune Disease Therapeutics Market
35. India Autoimmune Disease Therapeutics Market
36. Japan Autoimmune Disease Therapeutics Market
37. Australia Autoimmune Disease Therapeutics Market
38. South Korea Autoimmune Disease Therapeutics Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. Abbott Laboratories
40.2. AbbVie Inc.
40.3. Amgen Inc.
40.4. AstraZeneca PLC
40.5. Beckman Coulter, Inc.
40.6. Bio-Rad Laboratories, Inc.
40.7. BioAgilytix Labs, LLC
40.8. bioMerieux S.A.
40.9. Bristol-Myers Squibb Company
40.10. Eli Lilly and Company
40.11. Exagen, Inc.
40.12. F. Hoffmann-La Roche Ltd.
40.13. GlaxoSmithKline PLC
40.14. Johnson & Johnson Services, Inc.
40.15. Lupin Limited
40.16. Merck & Co., Inc.
40.17. Novartis AG
40.18. Pfizer, Inc.
40.19. Sanofi S.A.
40.20. Siemens Healthineers AG
40.21. Thermo Fisher Scientific Inc.
40.22. Trinity Biotech PLC
40.23. UCB S.A.
40.24. Werfen S.A.
List of Figures
FIGURE 1. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2025 VS 2032 (%)
FIGURE 15. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTIHYPERGLYCEMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTIHYPERGLYCEMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTIHYPERGLYCEMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL FUSION PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL FUSION PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CYTOKINE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CYTOKINE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CYTOKINE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PHOSPHODIESTERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PHOSPHODIESTERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PHOSPHODIESTERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL JAK INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL JAK INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL JAK INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL LUPUS ERYTHEMATOSUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL DISEASE PROGRESSION ALTERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL DISEASE PROGRESSION ALTERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL DISEASE PROGRESSION ALTERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL IMMUNE SYSTEM MODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL IMMUNE SYSTEM MODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL IMMUNE SYSTEM MODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL REDUCTION OF INFLAMMATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL REDUCTION OF INFLAMMATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL REDUCTION OF INFLAMMATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 133. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 134. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 135. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 136. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 137. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 138. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 139. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 140. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 141. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 151. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 152. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 153. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 154. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 155. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 156. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 158. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 159. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 160. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 161. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 162. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 163. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 164. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 165. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 167. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 168. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 169. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 170. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 171. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 172. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 173. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 174. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 176. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 177. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 187. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 188. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 189. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 190. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 191. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 192. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 194. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 195. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 196. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 197. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 198. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 199. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 200. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 201. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 202. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 203. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 204. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 205. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 206. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 207. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 208. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 209. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 210. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 211. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 212. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 213. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 214. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 215. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 216. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 223. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 224. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 225. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 226. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 227. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 228. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 230. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 231. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 232. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 233. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 234. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 235. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 236. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 237. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 238. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 239. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 240. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 241. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 242. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 243. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 244. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 245. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 246. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 247. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 248. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 249. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 252. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 253. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 254. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 255. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 256. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 259. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 260. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 261. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 262. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 263. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 264. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 265. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 266. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 267. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 268. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 269. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 270. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 271. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 272. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 273. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 274. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 275. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 276. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 277. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 278. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 279. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 280. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 281. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 282. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 283. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 284. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 285. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 286. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 287. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 288. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 289. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 290. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 291. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 292. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 293. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 294. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 295. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 296. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 297. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 298. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 299. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 300. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 301. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 302. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 303. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 304. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 305. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 306. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 307. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 308. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 309. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 310. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 311. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 312. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 313. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 314. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 315. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 316. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 317. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 318. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 319. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 320. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 321. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 322. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 323. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
TABLE 324. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 325. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
TABLE 326. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 327. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 328. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 329. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIO

Companies Mentioned

The companies featured in this Autoimmune Disease Therapeutics market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • bioMerieux S.A.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exagen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • UCB S.A.
  • Werfen S.A.

Table Information

Report AttributeDetails
No. of Pages192
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 209.53 Billion
Forecasted Market Value ( USD ) by 2032 $ 382.33 Billion
Compound Annual Growth Rate10.5%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Autoimmune Disease Therapeutics - Global Strategic Business Report - Product Image

Autoimmune Disease Therapeutics - Global Strategic Business Report

  • Report
  • 368 Pages
  • Global
From
Autoimmune Disease Drugs Market by Drug Class, Mechanism of Action, Route of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032 - Product Image

Autoimmune Disease Drugs Market by Drug Class, Mechanism of Action, Route of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Bispecific Antibodies Market - Global Forecast 2026-2032 - Product Image

Bispecific Antibodies Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Bispecific Antibodies - Global Strategic Business Report - Product Image

Bispecific Antibodies - Global Strategic Business Report

  • Report
  • 104 Pages
  • Global
From
Celiac Disease Treatment Market - Forecasts from 2025 to 2030 - Product Image

Celiac Disease Treatment Market - Forecasts from 2025 to 2030

  • Report
  • 145 Pages
  • Global
From

About the Autoimmune Drug Market

The Autoimmune Drug market is a subset of Immune Disorders Drugs, which are used to treat a variety of conditions caused by an overactive immune system. These drugs are designed to reduce inflammation, suppress the immune system, and prevent the body from attacking its own tissues. Common autoimmune diseases that are treated with these drugs include rheumatoid arthritis, psoriasis, lupus, and multiple sclerosis. Autoimmune drugs are typically administered orally, intravenously, or topically, depending on the condition being treated. They can be used alone or in combination with other treatments, such as physical therapy or lifestyle changes. Notable companies in the Autoimmune Drug market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.